Expression Profiles of GILZ and SGK-1 in Potentially Malignant and Malignant Human Oral Lesions.
GILZ
SGK-1
benign keratosis
epithelial dysplasia
human
immunohistochemistry
leukoplakia
squamous cell carcinoma
Journal
Frontiers in oral health
ISSN: 2673-4842
Titre abrégé: Front Oral Health
Pays: Switzerland
ID NLM: 9918227262706676
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
03
2021
accepted:
13
08
2021
entrez:
20
1
2022
pubmed:
21
1
2022
medline:
21
1
2022
Statut:
epublish
Résumé
Glucocorticoid-induced leucine zipper and serum-glucocorticoid-regulated kinase-1 (SGK-1) are major glucocorticoid-inducible proteins. Recent studies indicate the local production of cortisol in oral mucosa, which can impact the tissue generation of glucocorticoid-induced leucine zipper (GILZ) and SGK-1. Furthermore, GILZ and SGK-1 play pathogenic roles in a variety of cancers, but their status in potentially malignant (e.g., epithelial dysplasia) or malignant oral lesions remains unknown. This study tested the hypothesis that expression profiles of GILZ and SGK-1, along with the phosphorylated (active) form of SGK-1 (pSGK-1), are different in epithelial dysplasia than squamous cell carcinoma. Accordingly, archived paraffin-embedded biopsy samples were subjected to immunohistochemistry to establish tissue localization and the profile of proteins of interest, while hematoxylin-eosin stained tissues were used for histopathological assessment. Based on histopathological examinations, tissue specimens were categorized as displaying mild-moderate or severe epithelial dysplasia and squamous cell carcinoma; benign keratosis specimens served as controls. All the tissue specimens showed staining for SGK-1 and pSGK-1; however, while SGK-1 staining was primarily cytoplasmic, pSGK-1 was mainly confined to the cell membrane. On the other hand, all the tissue specimens displayed primarily nuclear staining for GILZ. A semi-quantitative analysis of immunohistochemistry staining indicates increased GILZ expression in epithelial dysplasia but reversal in squamous cell carcinoma to a level seen for benign keratosis. On the other hand, the SGK-1 and pSGK-1 expressions decreased for squamous cell carcinoma specimens compared with benign keratosis or dysplastic specimens. Collectively, in this cross-sectional study, immunostaining patterns for proteins of interest do not seemingly differentiate epithelial dysplasia from squamous cell carcinoma. However, subcellular localization and expression profiles for GILZ, SGK-1, and pSGK-1 are suggestive of differential functional roles in dysplastic or malignant oral lesions compared with benign keratosis.
Identifiants
pubmed: 35048019
doi: 10.3389/froh.2021.675288
pmc: PMC8757717
doi:
Types de publication
Journal Article
Langues
eng
Pagination
675288Informations de copyright
Copyright © 2021 Mozaffari and Abdelsayed.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oral Dis. 2021 Nov;27(8):1862-1880
pubmed: 33128420
Cell Physiol Biochem. 2017;43(3):1301-1308
pubmed: 28992614
Oncotarget. 2015 Mar 30;6(9):6931-43
pubmed: 25749387
J Chemother. 2020 Sep;32(5):263-267
pubmed: 32067575
Immunity. 1997 Dec;7(6):803-12
pubmed: 9430225
J Biol Chem. 2001 May 18;276(20):16649-54
pubmed: 11278764
Int J Biochem Cell Biol. 2017 Apr;85:166-174
pubmed: 28259749
Oral Oncol. 2017 Feb;65:23-32
pubmed: 28109464
Oral Dis. 2018 Mar;24(1-2):224-227
pubmed: 29480615
J Exp Clin Cancer Res. 2012 Jan 12;31:4
pubmed: 22240294
Biochem J. 2013 Jun 15;452(3):499-508
pubmed: 23581296
BMC Cancer. 2020 Feb 27;20(1):161
pubmed: 32106831
Mol Cell Biol. 1993 Apr;13(4):2031-40
pubmed: 8455596
Mol Cancer. 2009 Oct 08;8:83
pubmed: 19814803
Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240
pubmed: 29355614
Growth Factors. 2010 Dec;28(6):394-408
pubmed: 20919962
Nat Rev Immunol. 2017 Apr;17(4):233-247
pubmed: 28192415
J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):225-39
pubmed: 15336700
J Clin Invest. 2007 Jun;117(6):1605-15
pubmed: 17492054
J Clin Invest. 2015 Sep;125(9):3347-55
pubmed: 26325032
J Pharmacol Exp Ther. 2020 Dec;375(3):398-405
pubmed: 33008869
J Oral Maxillofac Surg. 2017 Sep;75(9):1980-1986
pubmed: 28189660
Br J Pharmacol. 2014 Feb;171(3):735-45
pubmed: 24172143
Am J Hypertens. 2014 Jun;27(6):846-56
pubmed: 24429675
Bio Protoc. 2019 Dec 20;9(24):
pubmed: 31867411
Oral Dis. 2018 Mar;24(1-2):179-183
pubmed: 29480606
Cell Death Dis. 2018 Apr 26;9(5):463
pubmed: 29695779
Oncogene. 2011 Jul 14;30(28):3198-206
pubmed: 21478911
Sci Rep. 2016 Jul 28;6:30405
pubmed: 27465291
PLoS One. 2014 Dec 08;9(12):e113795
pubmed: 25485633
Oral Dis. 2018 Mar;24(1-2):138-143
pubmed: 29480616
Cancer Lett. 2004 Jul 8;210(1):95-100
pubmed: 15172126
Cell Physiol Biochem. 2015;35(5):2006-18
pubmed: 25871776
Horm Cancer. 2014 Apr;5(2):72-89
pubmed: 24615402
Clin Dermatol. 2017 Sep - Oct;35(5):461-467
pubmed: 28916027
Exp Dermatol. 2014 Jun;23(6):369-374
pubmed: 24888781
Crit Rev Oncol Hematol. 2018 Jun;126:37-44
pubmed: 29759565
Int J Oncol. 2012 Nov;41(5):1751-61
pubmed: 22923130
Steroids. 2016 Jul;111:84-88
pubmed: 26930575
Breast Cancer Res Treat. 2012 Sep;135(2):469-79
pubmed: 22842983
J Cell Physiol. 2016 Nov;231(11):2368-73
pubmed: 27115293
J Cell Sci. 2019 Apr 9;132(7):
pubmed: 30837283
Cytokine Growth Factor Rev. 2010 Feb;21(1):11-9
pubmed: 20018552
J Pathol Transl Med. 2018 May;52(3):141-147
pubmed: 29621880
J Dent Res. 2012 Jan;91(1):97-103
pubmed: 22067259
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Acta Pharm Sin B. 2018 Sep;8(5):767-771
pubmed: 30245963
Ther Adv Med Oncol. 2020 Jul 15;12:1758835920940946
pubmed: 32728395
Gynecol Oncol. 2015 Sep;138(3):656-62
pubmed: 26115975
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
Oncotarget. 2015 Nov 10;6(35):37511-25
pubmed: 26462020
Tumour Biol. 2016 Mar;37(3):3017-24
pubmed: 26419593